In conclusion, our work strongly suggested that the expression of PD-L1 and HIF-1α protein may serve as attractive worse prognostic biomarkers for NSCLC patients and the combined evaluation of PD-L1 and HIF-1α may also be valuable for prognosis. This evidence concerns the gene HIF1A and non-small cell lung carcinoma.